Brought to you by 
Skyhawk raises $40mm through Series A round concurrent with Celgene deal
27 Jun 2018
Executive Summary
Skyhawk Therapeutics Inc. (small-molecule drug discovery) raised $40mm through its Series A round from Alexandria Venture Investments, GreatPoint Ventures, Celgene, ShangPharma Innovation, Agent Capital, and major family investors including Tim Disney, the Duke of Bedford, the Reilly family, and other others.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Skyhawk raises $40mm through Series A round concurrent with Celgene deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice